Stock Comparison
EXEL vs VRTX
Exelixis Inc and Vertex Pharmaceuticals Inc side by side — valuation, profitability, growth and risk.
Valuation
Market Cap
$13.77B
$124.70B
P/E (TTM)
18.1
29.2
Forward P/E
16.8
25.8
Price/Sales
5.8
10.2
Price/Book
6.9
6.4
EV/EBITDA
13.0
24.0
Dividend Yield
—
—
Profitability
Net Margin
35.10%
35.50%
Operating Margin
41.10%
38.10%
Return on Equity
41.00%
24.20%
Return on Assets
22.00%
12.10%
Growth (YoY)
Revenue Growth
10.00%
7.80%
Earnings Growth
43.60%
61.40%
Price & Risk
Beta
0.4
0.3
52-Week High
$55.15
$507.92
52-Week Low
$33.76
$362.50
Analyst Target
$49.50
$548.69
Compare EXEL and VRTX your own way
Try mrmarket.ai freeFigures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.